FDA authorizes new monkeypox point-of-care test, updates COVID-19 medical device shortages
The Food and Drug Administration Friday authorized for emergency use a molecular test to detect mpox (formerly known as monkeypox) at the point of care in lesion swab specimens from individuals whose health care provider suspects they have the virus.
In other news, FDA last week updated its list of medical device shortages and discontinued medical devices during the COVID-19 public health emergency.
Related News Articles
Headline
The Centers for Disease Control and Prevention released an advisory Oct. 29 on three unrelated cases of clade I mpox recently identified in California. The…
Headline
The California Department of Public Health Saturday reported the first known case of clade I mpox in the U.S. to the Centers for Disease Control and Prevention…
Headline
The World Health Organization Aug. 14 declared a global health emergency due to the recent mpox outbreak in Africa, the second mpox declaration in two years.…
Headline
As summer Pride parades and other large gatherings approach, Americans at high risk for mpox (monkeypox) exposure should ensure they are fully vaccinated with…
Headline
The Food and Drug Administration Friday authorized for emergency use a real-time polymerase chain reaction test to detect mpox (formerly known as…
Headline
In a study of men under age 50 who were eligible to receive the JYNNEOS vaccine to prevent monkeypox (mpox) during the U.S. outbreak this year, unvaccinated…